Cover Image

Temsirolimus in the treatment of advanced renal cell carcinoma

Bernard J. Escudier
  • Bernard J. Escudier
    Institut Gustave Roussy, Villejuif, France | escudier@igr.fr

Abstract

Temsirolimus is a novel inhibitor of mammalian target of rapamycin (mTOR), which is a central regulator of the response of tumour cells to growth and survival signals. When heavily pretreated patients with advanced solid tumours received intravenous (IV) temsirolimus over a broad dose range, antitumour activity was observed in various tumour types, including advanced renal cell carcinoma (RCC). A study of singleagent temsirolimus in patients with cytokine-refractory metastatic RCC subsequently demonstrated antitumour activity and encouraging progression- free survival and overall survival. Temsirolimus was generally well tolerated over the 3 dose levels tested (25 mg, 75 mg or 250 mg weekly as a 30-minute IV infusion). The most frequent grade 3 or 4 treatment-related adverse events reported (n=110) were hyperglycemia (17%), hypophosphatemia (13%), anemia (9%), and hypertriglyceridemia (6%). Results from a randomized phase III study that enrolled previously untreated patients with advanced RCC and poor-prognostic features have recently demonstrated a significant increase in overall survival (p=0.0089) for patients who received temsirolimus 25 mg IV, 30-minute infusion once weekly compared with those who received interferon-alpha up to 18 million units subcutaneously thrice weekly. On the basis of improved survival, temsirolimus can be considered a first-line treatment for patients with advanced RCC.

Keywords

Temsirolimus - Kidney cancer - Renal cell carcinoma - mTOR - Targeted therapy

Full Text:

FULL TEXT
Submitted: 2011-12-18 11:42:18
Published: 2011-12-18 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
717

Views:
FULL TEXT
115

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2011 Bernard J. Escudier

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185